Recruitment of immune cells across atrial endocardium in human atrial fibrillation.
暂无分享,去创建一个
Y. Iwasaki | H. Sawada | T. Aizawa | T. Yamashita | K. Sagara | A. Sekiguchi | T. Date | H. Suma | H. Tanabe
[1] M. Hirai,et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[2] G. Ávila,et al. Role of TGF-β on cardiac structural and electrical remodeling , 2008, Vascular health and risk management.
[3] T. Uejima,et al. Prevalence and prognosis of patients with atrial fibrillation in Japan: a prospective cohort of Shinken Database 2004. , 2008, Circulation journal : official journal of the Japanese Circulation Society.
[4] A. Goette,et al. Angiotensin II Receptor Blockade Reduces Tachycardia-Induced Atrial Adhesion Molecule Expression , 2008, Circulation.
[5] N. Lakkis,et al. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. , 2007, Journal of the American College of Cardiology.
[6] D. Kass,et al. Hemodynamic Modulation of Endocardial Thromboresistance , 2006, Circulation.
[7] D. Katritsis. Is atrial fibrillation an inflammatory disorder? , 2006, European heart journal.
[8] J. Svendsen,et al. Inflammation in the genesis and perpetuation of atrial fibrillation. , 2005, European heart journal.
[9] J. Langberg,et al. Atrial Fibrillation Increases Production of Superoxide by the Left Atrium and Left Atrial Appendage: Role of the NADPH and Xanthine Oxidases , 2005, Circulation.
[10] S. Yusuf,et al. Clinical ResearchHeart Rhythm DisorderPrevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2005 .
[11] Å. Sjöholm,et al. Endothelial inflammation in insulin resistance , 2005, The Lancet.
[12] G. Lip,et al. Endothelial dysfunction: methods of assessment and application to hypertension. , 2004, Current pharmaceutical design.
[13] J. Dernellis,et al. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. , 2004, European heart journal.
[14] G Hindricks,et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease , 2004, Heart.
[15] Bruce M Psaty,et al. Inflammation as a Risk Factor for Atrial Fibrillation , 2003, Circulation.
[16] R. Goldberg,et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. , 2003, The American journal of cardiology.
[17] C. Lau,et al. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. , 2003, The American journal of cardiology.
[18] TakeshiYamashita,et al. Thrombomodulin and Tissue Factor Pathway Inhibitor in Endocardium of Rapidly Paced Rat Atria , 2003 .
[19] I. Gelder,et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2003 .
[20] A L Waldo,et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.
[21] H. Crijns,et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.
[22] A. Goette,et al. Downregulation of Endocardial Nitric Oxide Synthase Expression and Nitric Oxide Production in Atrial Fibrillation: Potential Mechanisms for Atrial Thrombosis and Stroke , 2002, Circulation.
[23] Peter Libby,et al. Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis , 2002, Circulation research.
[24] Zoltan Szalay,et al. Structural correlate of atrial fibrillation in human patients. , 2002, Cardiovascular research.
[25] I. V. Van Gelder,et al. Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. , 2002, Cardiovascular research.
[26] P. Libby,et al. Inflammation and Atherosclerosis , 2002, Circulation.
[27] I. V. Van Gelder,et al. Rate control versus electrical cardioversion for atrial fibrillation: A randomised comparison of two treatment strategies concerning morbidity, mortality, quality of life and cost-benefit - the RACE study design. , 2002, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.
[28] Cynthia A. Carnes,et al. C-Reactive Protein Elevation in Patients With Atrial Arrhythmias: Inflammatory Mechanisms and Persistence of Atrial Fibrillation , 2001, Circulation.
[29] D. Singer,et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.
[30] K. V. van Dijk,et al. Macrophage scavenger receptor class A: A multifunctional receptor in atherosclerosis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[31] R. Terkeltaub,et al. Chemokines and atherosclerosis. , 1998, Current opinion in lipidology.
[32] D. Levy,et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.
[33] R. Ross,et al. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[34] M. Russo,et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. , 1997, Circulation.
[35] D. Steinberg,et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[36] P. Wolf,et al. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. , 1985, JAMA.
[37] A. Waldo. Increased Inflammatory Cell Infiltration in the Atrial Myocardium of Patients With Atrial Fibrillation , 2009 .
[38] A. Waldo. Angiotensin II Receptor Blockade Reduces New-Onset Atrial Fibrillation and Subsequent Stroke Compared to Atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study , 2006 .
[39] R. Kronmal,et al. Relation of Elevated C-Reactive Protein and Interleukin-6 Levels to Left Atrial Size and Duration of Episodes in Patients With Atrial Fibrillation , 2005 .
[40] T. Ohe,et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. , 2003, Thrombosis research.
[41] B L Langille,et al. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress. , 1995, Arteriosclerosis, thrombosis, and vascular biology.